EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Treatment of acute promyelocytic leukemia with arsenic trioxide: clinical and basic studies



Treatment of acute promyelocytic leukemia with arsenic trioxide: clinical and basic studies



Leukemia & Lymphoma 42(6): 1265-1273



Arsenic trioxide (As2O3) has recently been identified as an effective drug in the treatment of newly diagnosed and relapsed acute promyelocytic leukemia (APL) without cross-resistance to all-trans retinoic acid and achieved complete remission rates of 80-90% according to most reports. With intravenous infusion at a dose of 0.08-0.16 mg/kg daily, a course of 28-42 days is required to induce remission. As2O3 in combination with chemotherapy as postremission therapy results in longer survival than arsenic alone. In vitro, As2O3 exerts dose-dependent dual effect; triggering apoptosis at relatively high concentration (0.5-2.0 micromol/l), which is associated with the disruption of mitochondrial transmembrane potentials, while inducing partial differentiation at low concentration (0.1-0.5 micromol/l), which might be related to retinoic acid signaling pathway. Importantly, at both concentrations, As2O3 can degrade PML (promyelocytic leukemia) -RAR alpha (retinoic acid receptor), an oncoprotein that has a central role in leukemogenesis.

(PDF emailed within 0-6 h: $19.90)

Accession: 047830535

Download citation: RISBibTeXText

PMID: 11911407

DOI: 10.3109/10428190109097751



Related references

Treatment of acute promyelocytic leukemia and other hematologic malignancies with arsenic trioxide: Review of clinical and basic studies. International Journal of Hematology 78(1): 32-39, July, 2003

Arsenic trioxide in the treatment of acute promyelocytic leukemia Basic mechanisms and clinical results. Annals of Hematology 77(SUPPL 2): S19, 1998

Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. Blood 94(10): 3315-3324, 1999

Studies on the clinical efficacy and pharmacokinetics of low-dose arsenic trioxide in the treatment of relapsed acute promyelocytic leukemia: a comparison with conventional dosage. Leukemia 15(5): 735-741, 2001

Clinical observation on arsenic trioxide in the treatment of acute promyelocytic leukemia. Experimental Hematology (Charlottesville) 25(8): 866, 1997

Clinical usefulness of arsenic trioxide in the treatment of acute promyelocytic leukemia. Haematologica 87(5): 452-453, 2002

Comparison of clinical outcomes of patients with relapsed acute promyelocytic leukemia induced with arsenic trioxide and consolidated with either an autologous stem cell transplant or an arsenic trioxide-based regimen. Biology of Blood and Marrow Transplantation 15(11): 1479-1484, 2009

Clinical observation on arsenic trioxide in the treatment of relapsed acute promyelocytic leukemia. Blood 92(10 SUPPL 1 PART 1-2): 404A, Nov 15, 1998

Treatment of acute promyelocytic leukemia with arsenic trioxide: clinical results and open questions. Expert Review of Anticancer Therapy 13(9): 1035-1043, 2014

Clinical observation and following up of two administration methods of arsenic trioxide in treatment of acute promyelocytic leukemia. Zhonghua Yi Xue Za Zhi 84(5): 405-408, 2004

New retinoids and arsenic compounds for the treatment of refractory acute promyelocytic leukemia: clinical and basic studies for the next generation. Cancer ChemoTherapy and Pharmacology 40 Suppl: S36-S41, 1997

Clinical observations on arsenic trioxide and all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 92(10 SUPPL 1 PART 1-2): 483A, Nov 15, 1998

Use of arsenic trioxide in the treatment of acute promyelocytic leukemia II Clinical efficacy and pharmacokinetics in relapsed patients. Blood 89(9): 3354-3360, 1997

Ascorbic Acid - Modulation Of Arsenic Trioxide Toxicity: Implication For The Clinical Treatment Of Acute Promyelocytic Leukemia. Metal Ions in Biology and Medicine 10(): 413-418, 2008